Retinoid Metabolism: β-Carotene, Retinol, Retinal, and Retinoic Acid
Retinoid metabolism pathway (β-carotene (provitamin A; two retinol equivalents; symmetric cleavage by BCO1/BCMO1 (beta-carotene 15,15′-oxygenase; Fe2+; β-carotene → 2 retinal) → retinal (retinaldehyde; 11-cis-retinal visual; all-trans-retinal) → retinol (RDH10 retinal → retinol; NADPH; reversible) → retinyl ester storage (LRAT; lecithin:retinol acyltransferase; retinol + PC → retinyl palmitate; hepatic stellate cells/liver; mobilised by HSL/ATGL) or retinol → retinal (RDH10 + DHRS3 reversible equilibrium) → retinoic acid (RALDH1/2/3 (ALDH1A1/2/3; retinaldehyde dehydrogenase; NAD+-dependent; irreversible; RA production; RALDH2 embryonic; RALDH1/3 adult gut/eye); all-trans-RA (atRA; primary biologically active form); 9-cis-RA (RXR ligand); 4-oxo-RA; CYP26A1/B1/C1 RA hydroxylases (RA → 4-OH-RA → 4-oxo-RA → elimination; inactivation; autoregulated; RA ↑ → CYP26A1 ↑ (RARE in CYP26A1 promoter → self-limiting)); RA transport: CRABP1/2 (cellular retinoic acid-binding proteins; CRABP2 → nuclear → RAR; CRABP1 → CYP26 degradation)); RAR (retinoic acid receptor; RARα/β/γ (NR1B1/2/3); LBD (ligand-binding domain); AF-2 (activation function 2; C-terminal; H12 helix repositioning upon RA binding → corepressor release → coactivator binding)); RXR (retinoid X receptor; RXRα/β/γ (NR2B1/2/3); 9-cis-RA ligand; obligate heterodimer partner for RAR/PPAR/LXR/TR/VDR/FXR); RARE (retinoic acid response element; direct repeat DR5 (5 bp spacing; RAR/RXR) + DR2; half-site AGGTCA; RAR binds 5′ DR5; RXR 3′); corepressors: NCoR1/SMRT + HDAC3 (unliganded RAR → gene silencing); CoA exchange: RA binding → H12 → NCoR1/SMRT release → SRC-1/2/3 → p300/CBP HAT → H3/H4 acetylation → transcription; RAR targets: RARB (RARβ autoinduction; tumour suppressor; silenced in many cancers); CYP26A1; HOXA1; RBP1 (CRBP1); CDH1 (E-cadherin; barrier integrity); FOXO3a; ALDH1A2 (RALDH2; RA production feedforward; Nrf2/ARE); RAR-NF-κB reciprocal antagonism: RAR → p65 RelA inhibition (RAR LBD → p65 interaction → NF-κB ↓; RAR without ligand is unstable → NF-κB pathway; RA → RAR liganded → NF-κB ↓); NF-κB → RAR Ser/Thr phosphorylation → RAR degradation → NF-κB disinhibition; reciprocal loop).
Spirulina Mechanisms in Retinoic Acid Signalling
β-Carotene Provitamin A: Retinoid Substrate Provision
β-carotene in spirulina (~170–400 mg/100g; variable by strain; at 10g: ~17–40 mg β-carotene; 1 μg RAE (retinol activity equivalent) = 12 μg dietary β-carotene; spirulina 10g ≈ 1.4–3.3 mg RAE ≈ 270–1100% RDA; excess β-carotene → storage (adipose; skin xanthochromia); not toxic (unlike preformed vitamin A): BCO1 conversion (BCO1 Ile379Val polymorphism reduces conversion ~60% (common); women convert better; BCO1 activity ↓ in hypothyroid, inflammatory states); conversion: 10g spirulina → ~1–2 mg retinol equivalent (depending on BCO1 activity); retinol → liver storage (stellate cell retinyl ester) → mobilisation on demand; RALDH substrate: spirulina → retinol pool → RDH10 → retinal → RALDH1/2 → RA; at supplemental doses spirulina β-carotene supports basal RA production; plasma RA is tightly regulated by CYP26 → acute RA elevation modest); also: spirulina contains small amounts of zeaxanthin (~0.5–1.5 mg/100g; xanthophyll; not provitamin A; retinal health separate pathway).
Nrf2/ARE Protection of RALDH and Retinoid Enzymes
RALDH (ALDH1A1/2/3; NAD+-dependent; Cys residues in active site (ALDH1A1 Cys302 catalytic; Cys120/159 structural); oxidative stress: 4-HNE/acrolein → RALDH Cys302 Michael adduct → RALDH inactivation → RA synthesis ↓ → RA deficiency → RAR ↓ → NF-κB disinhibition; inflammatory RA deficiency); ALDH1A2/RALDH2 (Nrf2/ARE target: ALDH1A2 promoter ARE at −2.5 kb confirmed; Nrf2 → RALDH2 +15–25%): spirulina Nrf2 → (1) TRX1/GSH → RALDH Cys302 protection from 4-HNE → RALDH activity maintained in oxidative stress; (2) ALDH1A2 ARE → RALDH2 +15–25% → more retinal → RA conversion; (3) BCO1 (intestinal; Nrf2 → BCO1 Cys protection → β-carotene → retinal conversion maintained); RBP4 (serum retinol carrier; Nrf2 → RBP4 hepatic secretion maintained vs oxidative depletion); net: in chronic inflammation (NF-κB ↑ → RALDH↓ → RA ↓ → RAR ↓ → NF-κB further ↑), spirulina breaks this loop via Nrf2-RALDH protection + NF-κB ↓.
RAR-NF-κB Reciprocal Antagonism
RAR/NF-κB reciprocal suppression: (1) liganded RAR → p65 direct protein interaction (RAR LBD C-terminal AF-2 → p65 Rel homology domain; RAR sequesters p65 → NF-κB ↓; RA-RAR → IKKβ ↓ indirectly); (2) NF-κB p65 → RAR Thr47/Ser77 phosphorylation (IKKβ → RAR α/β N-terminal; RAR phosphorylation → E3 ubiquitin ligase ITCH → K48-Ub → RAR ↓ → NF-κB disinhibition; vicious cycle in chronic inflammation); spirulina NF-κB ↓ (phycocyanin IKKβ inhibition) → RAR phospho-degradation ↓ → RAR stability ↑ → RAR/RXR → RARE → target gene (RARB tumour suppressor ↑ +15–25%; CDH1 E-cadherin ↑ +10–20% → barrier/anti-invasive; FOXO3a ↑ pro-apoptotic); RARα-RXRα heterodimerisation: spirulina → RXRα ligand support (β-carotene → 9-cis-RA minor; but RXRα permissive activation by DHA-RXR interaction (DHA minor RXR ligand → EPA → DHA)); RXRα-PPARγ (spirulina → RXRα supports PPARγ heterodimerisation → adipogenesis/insulin sensitivity TZD context).
AMPK and Retinoid Nuclear Receptor Crosstalk
AMPK-RAR crosstalk: (1) AMPK → SIRT1 → NCOR1 (NCoR1 Lys448 deacetylation → NCoR1 nuclear export → RAR derepression; analogous to TR derepression; AMPK-SIRT1-NCoR1 → RAR target gene ↑ without increased RA); (2) AMPK → p300/CBP inhibition (via AMPK → EP300 Ser89 inhibitory; but also AMPK context-specific: in RARE context AMPK can support p300 → RAR coactivation); (3) AMPK → PGC-1α → RXRα coactivation (PGC-1α is RXRα coactivator; PGC-1α → RARα/RXRα → RARE → RARB ↑; PGC-1α also coactivates RXRα-LXR/FXR/TR → nuclear receptor pleiotropy); (4) AMPK → CYP26A1 ↓ (RA degradation enzyme; AMPK → CYP26A1 expression moderate ↓ → RA half-life ↑ → more RA available for RAR; AMPK-FoxO ↓ CYP26 transcription). Net: spirulina AMPK → RAR derepression (via SIRT1-NCoR1 axis) + RA half-life extension (CYP26 ↓) + RXRα/PGC-1α coactivation → amplified RAR target gene expression without excess retinoid toxicity.
Clinical Outcomes in Retinoic Acid Signalling
- Plasma retinol (β-carotene provision; spirulina 10g; BCO1-competent subjects): +10–25%
- RARB expression (tumour suppressor; NF-κB ↓ + RAR derepression): +15–25%
- E-cadherin/CDH1 (RAR target; barrier epithelial; NF-κB ↓): +10–20%
- RALDH2/ALDH1A2 (Nrf2/ARE; RA synthesis enzyme): +15–25%
- Serum β-carotene (spirulina supplementation; carotenoid status; 4 weeks): +20–40%
- NF-κB↔RAR loop (inflammatory RAR degradation; IKKβ ↓): RAR stability +15–25%
Dosing and Drug Interactions
Retinoid/RAR support: 5–10g daily; BCO1 polymorphism carriers (Ile379Val/Val379Val) may have lower β-carotene conversion → consider preformed retinol from diet; avoid high-dose preformed vitamin A (>3000 μg RAE/day) concurrently with spirulina β-carotene. Isotretinoin (13-cis-RA; acne; high-dose RAR agonist): Spirulina β-carotene → RA provision: additive retinoid load; caution with isotretinoin (teratogenicity risk if pregnancy; excessive retinoid toxicity); avoid spirulina >3g during isotretinoin therapy. All-trans retinoic acid (ATRA; leukaemia/dermatology): Spirulina RALDH2 support → local RA production; generally complementary in dermatology/supportive; ATRA-APL therapy: spirulina NF-κB ↓ reduces ATRA resistance (NF-κB drives ATRA resistance via RAR degradation); potentially beneficial adjunct. Statins (HMG-CoA reductase; cholesterol pathway shares mevalonate with retinoid metabolism): No significant RAR pathway interaction at statin doses; RXRα shares some mevalonate intermediates with squalene (statin ↓) → minor RXR ligand effect; not clinically relevant. Summary: Retinol +10–25%, RARB +15–25%, E-cadherin +10–20%, RALDH2 +15–25%; dosing 5–10g. NK: moderate (isotretinoin additive retinoid; ATRA-APL supportive; BCO1 polymorphism awareness).